Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Similar articles for PubMed (Select 22147245)

1.

NOD2 polymorphism predicts response to treatment in Crohn's disease--first steps to a personalized therapy.

Niess JH, Klaus J, Stephani J, Pflüger C, Degenkolb N, Spaniol U, Mayer B, Lahr G, von Boyen GB.

Dig Dis Sci. 2012 Apr;57(4):879-86. doi: 10.1007/s10620-011-1977-3. Epub 2011 Dec 7.

2.

Response to medical treatment in patients with Crohn's disease: the role of NOD2/CRAD15, disease phenotype, and age of diagnosis.

Weiss B, Lebowitz O, Fidder HH, Maza I, Levine A, Shaoul R, Reif S, Bujanover Y, Karban A.

Dig Dis Sci. 2010 Jun;55(6):1674-80. doi: 10.1007/s10620-009-0936-8. Epub 2009 Aug 20.

PMID:
19693669
3.

Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation.

Lu C, Waugh A, Bailey RJ, Cherry R, Dieleman LA, Gramlich L, Matic K, Millan M, Kroeker KI, Sadowski D, Teshima CW, Todoruk D, Wong C, Wong K, Fedorak RN.

World J Gastroenterol. 2012 Sep 28;18(36):5058-64. doi: 10.3748/wjg.v18.i36.5058.

4.

[NOD2/CARD15 mutations and genotype-phenotype correlations in patients with Crohn's disease. Hungarian multicenter study].

Lakatos L, Lakatos PL, Willheim-Polli C, Reinisch W, Ferenci P, Tulassay Z, Molnár T, Kovács A, Papp J, Szalay F; Hungarian IBD Study Group.

Orv Hetil. 2004 Jul 4;145(27):1403-11. Hungarian.

PMID:
15320482
5.

Age-of-onset-dependent influence of NOD2 gene variants on disease behaviour and treatment in Crohn's disease.

Posovszky C, Pfalzer V, Lahr G, Niess JH, Klaus J, Mayer B, Debatin KM, von Boyen GB.

BMC Gastroenterol. 2013 May 2;13:77. doi: 10.1186/1471-230X-13-77.

6.

The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease.

Brand S, Staudinger T, Schnitzler F, Pfennig S, Hofbauer K, Dambacher J, Seiderer J, Tillack C, Konrad A, Crispin A, Göke B, Lohse P, Ochsenkühn T.

Inflamm Bowel Dis. 2005 Jul;11(7):645-52.

PMID:
15973118
7.

Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease.

Cucchiara S, Latiano A, Palmieri O, Canani RB, D'Incà R, Guariso G, Vieni G, De Venuto D, Riegler G, De'Angelis GL, Guagnozzi D, Bascietto C, Miele E, Valvano MR, Bossa F, Annese V; Italian Society of Pediatric Gastroenterology and Nutrition.

J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):171-9.

PMID:
17255827
8.

NOD2/CARD15 mutations in Croatian patients with Crohn's disease: prevalence and genotype-phenotype relationship.

Cukovic-Cavka S, Vermeire S, Hrstic I, Claessens G, Kolacek S, Jakic-Razumovic J, Krznaric Z, Grubelic K, Radic D, Misak Z, Jadresin O, Rutgeerts P, Vucelic B.

Eur J Gastroenterol Hepatol. 2006 Aug;18(8):895-9.

PMID:
16825909
9.

NOD2/CARD15 gene polymorphisms in Crohn's disease: a genotype- phenotype analysis.

Heresbach D, Gicquel-Douabin V, Birebent B, D'halluin PN, Heresbach-Le Berre N, Dreano S, Siproudhis L, Dabadie A, Gosselin M, Mosser J, Semana G, Bretagne JF, Yaouanq J.

Eur J Gastroenterol Hepatol. 2004 Jan;16(1):55-62.

PMID:
15095853
10.

Association of NOD2/CARD15 mutations on Crohn's disease phenotype in an Italian population.

Bianchi V, Maconi G, Ardizzone S, Colombo E, Ferrara E, Russo A, Tenchini ML, Porro GB.

Eur J Gastroenterol Hepatol. 2007 Mar;19(3):217-23.

PMID:
17301648
11.

Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: a project of the European Collaborative Study Group on Inflammatory Bowel Disease.

Odes S, Friger M, Vardi H, Claessens G, Bossuyt X, Riis L, Munkholm P, Wolters F, Yona H, Hoie O, Beltrami M, Tsianos E, Katsanos K, Mouzas I, Clofent J, Monteiro E, Messori A, Politi P, O'Morain C, Limonard C, Russel M, Vatn M, Moum B, Stockbrugger R, Vermeire S; European Collaborative Study Group on Inflammatory Bowel disease.

Inflamm Bowel Dis. 2007 Jul;13(7):874-81.

PMID:
17278126
12.

NOD2/CARD15 does not influence response to infliximab in Crohn's disease.

Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP; Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France.

Gastroenterology. 2002 Jul;123(1):106-11.

PMID:
12105838
13.

Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation.

Büning C, Genschel J, Bühner S, Krüger S, Kling K, Dignass A, Baier P, Bochow B, Ockenga J, Schmidt HH, Lochs H.

Aliment Pharmacol Ther. 2004 May 15;19(10):1073-8.

14.

NOD2/CARD15 genotype and phenotype differences between Ashkenazi and Sephardic Jews with Crohn's disease.

Karban A, Waterman M, Panhuysen CI, Pollak RD, Nesher S, Datta L, Weiss B, Suissa A, Shamir R, Brant SR, Eliakim R.

Am J Gastroenterol. 2004 Jun;99(6):1134-40.

PMID:
15180737
15.

Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease.

Gutiérrez A, Scharl M, Sempere L, Holler E, Zapater P, Almenta I, González-Navajas JM, Such J, Wiest R, Rogler G, Francés R.

Gut. 2014 Feb;63(2):272-80. doi: 10.1136/gutjnl-2012-303557. Epub 2013 Feb 1.

PMID:
23376290
16.

New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.

Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Norman GL, Szamosi T, Papp J; Hungarian IBD Study Group, Lakatos PL.

Am J Gastroenterol. 2008 Mar;103(3):665-81. Epub 2007 Nov 28.

PMID:
18047543
17.

NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report.

Barreiro-de Acosta M, Ouburg S, Morré SA, Crusius JB, Lorenzo A, Potel J, Salvador-Peña A, Domínguez-Muñoz JE.

Rev Esp Enferm Dig. 2010 Oct;102(10):591-5.

18.

Crohn's disease is associated with polymorphism of CARD15/NOD2 gene in a Hungarian population.

Nagy Z, Karádi O, Rumi G, Rumi G Jr, Pár A, Mózsik G, Czirják L, Süto G.

Ann N Y Acad Sci. 2005 Jun;1051:45-51.

PMID:
16126943
19.

NOD2 gene mutations in ulcerative colitis: useless or misunderstood?

Freire P, Cardoso R, Figueiredo P, Donato MM, Ferreira M, Mendes S, Ferreira AM, Vasconcelos H, Portela F, Sofia C.

Int J Colorectal Dis. 2014 Jun;29(6):653-61. doi: 10.1007/s00384-014-1850-x. Epub 2014 Mar 22.

PMID:
24651958
20.

Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients.

Papp M, Altorjay I, Norman GL, Shums Z, Palatka K, Vitalis Z, Foldi I, Lakos G, Tumpek J, Udvardy ML, Harsfalvi J, Fischer S, Lakatos L, Kovacs A, Bene L, Molnar T, Tulassay Z, Miheller P, Veres G, Papp J; Hungarian IBD Study Group, Lakatos PL.

Inflamm Bowel Dis. 2007 Aug;13(8):984-92.

PMID:
17417801
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk